Ijem

A day after Alkermes Plc (NASDAQ: ALKS) revealed positive results from ALKS 5461 for major depressive disorder treatment, JPMorgan upgraded the shares from Neutral to an Overweight rating. The firm also boosted the target price from $51 to $78 on the company's shares, saying that the drug candidate...